Sign in
Taking peoplePhase 4

Allopurinol to help prevent complications of decompensated cirrhosis of the liver

Tests allopurinol against placebo in adults with decompensated cirrhosis of the liver.

Key facts

Who runs it
Bangladesh Medical University
Where
Bangladesh1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
Role of Allopurinol in Prevention of Complications Related to Decompensated Cirrhosis of Liver
Status
Recruiting
Phase
Phase 4
People taking part
54 people, planned
Started
10 Sept 2025
Expected to end
Jul 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Allopurinol Tablet
  • Placebo
Record updated
2 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with decompensated cirrhosis of the liver, from any cause. Cirrhosis is scarring of the liver, and decompensated means it has started to cause serious problems. The trial tests whether allopurinol helps prevent complications.

Age
18 to 70 years
Sex
All sexes
Disease stage
Decompensated cirrhosis of the liver, any cause, with a CTP (Child-Pugh) score of B or C.
Earlier treatment
People currently taking medicines that interact with allopurinol cannot join. Examples: azathioprine, mercaptopurine, Cyclophosphamide, Thiazide diuretics, Warfarin, Theophyllin.

Main reasons for not taking part

  • Known allergy to allopurinol
  • Active HE, SBP or HRS-AKI, or any of these in the last 4 weeks. These are serious liver-related brain, belly infection or kidney problems.
  • Advanced kidney problems (creatinine clearance <30 mL/min)
  • Pregnant or breastfeeding women
  • Severe other illness, such as uncontrolled heart disease, cancer or severe infection

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • • Adult patients (age : 18-70 years) diagnosed with Decompensated cirrhosis of liver with any etiology of cirrhosis ; CTP score B or C

Who cannot take part

  • • Patients with known hypersensitivity or allergy to allopurinol; Patients with active HE or SBP or HRS-AKI or a history of any of these events within the last 4 weeks; Patients with advanced renal impairment (e.g., creatinine clearance <30 mL/min); Pregnant or breastfeeding women; Patients with severe comorbidities (e.g., uncontrolled cardiovascular disease, cancer, or severe infections); Patients currently using medications that interact with allopurinol (e.g., azathioprine, mercaptopurine, Cyclophosphamide, Thiazide diuretics ,Warfarin, Theophyllin )

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 70 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Cirrhosis, a leading cause of global mortality, progresses to life-threatening complications like ascites, hepatic encephalopathy, and hepatorenal syndrome. Oxidative stress and gut-liver axis dysfunction drive disease progression. Allopurinol, a xanthine oxidase inhibitor, has shown potential in reducing complications in cirrhosis, but robust clinical evidence is lacking. This study will evaluate allopurinol's efficacy in preventing complications in decompensated cirrhosis.

Read full original descriptionShow less

This study aims to assess whether allopurinol reduces cirrhosis-related complications (ascites, variceal bleeding, hepatic encephalopathy, SBP, HRS-AKI) and improves MELD/CTP scores in Child-Pugh B/C cirrhosis patients.

This study will select 54 patients with decompensated cirrhosis (Child-Pugh B/C). Patients aged 18-70 years, with any etiology of cirrhosis (viral, alcoholic, NAFLD). Patients with acute decompensation, allopurinol hypersensitivity, advanced renal impairment (CrCl <30 mL/min), pregnancy, or concurrent use of interacting drugs.

This randomized controlled trial will be conducted in Hepatology department of BMU after IRB clearance. 54 patients aged 18 to 70 years with Child-Pugh class B or C cirrhosis, admitted to or attending the Outpatient Department of Hepatology at Bangladesh Medical University will be enrolled. After thorough clinical and laboratory evaluation and informed consent, patients will be randomized in a either an allopurinol treatment group or a standard care group with placebo ; 27 participants in each group by block randomization. one group will receive oral Allopurinol (titrated from 100 mg to 300 mg daily for six months) along with standard medical therapy. Another Group will receive same dose of Placebo along with standard medical therapy . Patients will be followed at 6 month to see the progression of cirrhosis-related complications. Data collection will include clinical parameters, laboratory tests, imaging, and endoscopy.

All data will be analyzed using the statistical package SPSS (version 29.0 IBM Corp: Armonk NY, USA). Demographic and baseline clinical characteristics will be analyzed using the chi-square test for categorical variables. For continuous variables that follow a normal distribution, the Student's t-test will be applied. Time to first complication will be analyzed using the Cox proportional hazards model, and Kaplan-Meier curves will be used to compare event-free survival between groups.

The study protocol is approved by the institutional review board. Written informed consent (Bengali version) will be obtained, ensuring confidentiality and voluntary participation. Participants may withdraw anytime.

If effective, allopurinol will offer a low-cost, widely accessible therapy to prevent complications and improve survival in decompensated cirrhosis. To the best of my knowledge this is the first study in Bangladesh to evaluate the efficacy of Allopurinol in prevention of cirrhosis associated complications.

The 2 groups in the trial

  • DrugExisting treatment, for comparison

    Patients will recieve 300mg Allopurinol along with standard medical therapy

    Treatment: Allopurinol Tablet

  • PlaceboPlacebo, for comparison

    Patients will recieve same dose of matched Placebo along with standard medical therapy

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Role of Allopurinol in Prevention of Complications Related to Decompensated Cirrhosis of Liver'
Plain-language title
Allopurinol to help prevent complications of decompensated cirrhosis of the liverGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Criteria questions
Built from NCT07800598, who can take part
Record updated
2 September 2026